INCY Incyte Earnings and EPS analysis

?
Relative Growth: Rel. Growth: 97
Relative Strength: Rel. Strength: 61
Relative Valuation: Rel. Valuation: 90
Relative Profitability: Rel. Profitability: 99

EPS in 2026 (TTM): $7.29

Last Report Period Date: Mar 31, 2026

As of June this year, based on Incyte's latest financial report, the company's current EPS (TTM) is $7.29. In 2025, INCY reported a per-share earnings of $6.59, which represents an increase compared to the EPS of $0.16 recorded in 2024. Incyte's EPS for the quarterly period ending on Mar 31, 2026 was $1.52.

INCY earnings history

Historical annual and quarterly earnings per share (EPS) data for Incyte
EPS (TTM)
$7.29
EPS Growth YoY (Quarterly)
85.4%
EPS (Quarterly)
$1.52
EPS Growth (Quarterly)
0.7%

The yearly EPS in 2025 was $6.59, an increase of 4,018.8% compared to $0.16 recorded in 2024. For the quarter ending Mar 31, 2026, the EPS was $1.52, reflecting a 85.4% increase compared to the same quarter a year earlier. The trailing twelve months (TTM) EPS as of March 2026 is $7.29. In 2024, the annual EPS was $0.16, showing a decrease of 94% compared to 2023.

INCY earnings chart

INCY EPS growth history

Earnings per share growth rates over time
EPS Growth YoY (Quarterly)
85.4%
EPS growth YoY
4,018.8%
EPS growth 3Y avg
62.7%
EPS growth 5Y avg
N/A

Incyte has recorded a growth in earnings per share of 85.4% over the past 12 months (YoY, quarterly). Looking at a longer timeframe, the company recorded an average EPS annual growth rate of 62.7% per year for the last 3 years. A ten-year view shows that INCY has seen an average earnings per share growth of 66.6% per year.

INCY Earnings Waterfall

Breakdown of revenue, profit and net income for Incyte

INCY Earnings vs Peers

What are the earnings of INCY compared to its peers
Stock name Price to Earnings EPS grwoth 1Y EPS grwoth 3Y EPS grwoth 5Y
INCY Incyte Corp 13.89 4,018.8% 62.7% N/A
PFE Pfizer Inc 19.61 -3.5% -37.4% -3.7%
NVS Novartis AG 21.14 21.8% 31.2% 15.2%
AMGN Amgen Inc 23.87 88.1% 5.6% 2.9%
LGND Ligand Pharmaceuticals Inc 29.83 3,027.3% N/A N/A
LLY ELI LILLY & Co 39.88 95.6% 49.2% 27.5%
ARDX Ardelyx Inc N/A -52.9% N/A N/A
GERN Geron Corp N/A 51.9% N/A N/A

All data is based on quarterly TTM periods, unless otherwise specified.